Vor Bio Inc.
NASDAQ · VOR·Boston, MA·Small-cap·Phase 3
Focused on transforming the treatment of autoimmune diseases through telitacicept, a dual BAFF/APRIL inhibitor fusion protein licensed from RemeGen. Advancing telitacicept through global Phase 3 trials in generalized myasthenia gravis and primary Sjogren's disease, with approvals already in China for SLE, RA, and gMG.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Vor Bio Corporate Presentation March 2026 | Corporate overview | March 1, 2026 | 42 |